



(Translation of the original press release)

5th April 2024

HOIST Corporation

Representative chairman and CSO: Chihaya Kakinuma
Executive Officer, Head of Management Division, CFO: Koji Abe
(Representative phone number: 072-707-2760)

Announcement of a presentation at AACR regarding HM-001, currently in development

We are pleased to inform that we have presented the progress of the HM-001 (sodium chlorite) programme, an investigational medicinal product that utilizes the MA-T[®] technology¹ at the American Association for Cancer Research (AACR) Annual Meeting², held in San Diego, USA from 5th Apr 2024.

By utilizing the Patient Derived Xenograft (PDX)³ from low grade bladder cancer patients, we have shown that HM-001 shows promise for low- and intermediate- risk bladder cancer, which consists of 70% of bladder cancer patients.

In addition, we believe that we are the only organization able to evaluate low grade bladder cancer by utilizing PDX.

We shall be continuing to use our company's proprietary technology to further our development programme that includes the HM-001 programme, currently in Phase I clinical studies.

¹ MA-T[®] is an abbreviation of Matching Transformation System[®], and is a revolutionary technology to control oxidation. By generating the required amount of activated species (water soluble radical) from sodium chlorite when necessary, it is possible to deactivate various virus (including epidemic virus) and bacteria. In addition, by controlling the activation, it may be possible to develop highly difficult chemical reactions, and improve the functionality of polymers and applying them to devices, or applying to agricultural and medical uses. (taken from MA-T industrial association, <https://matjapan.jp/mat/>)

² Please refer to the following website:

<https://www.aacr.org/meeting/aacr-annual-meeting-2024/>

³ Please refer to the following website for details regarding our proprietary drug discovery platform technology:
<https://hoist-jp.com/en/home/technical-info/#pdx>